5,0
26. Aug. 2025
Mitarbeiter (anonym)
Ehemaliger Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Amazing intellectual atmosphere for R&D
Kontras
Effectively assimilated by Roche and now just another mega-corp; pay is slightly below market rate as they see themselves as “the Harvard of industry.” Senior management makes big slash and burn cuts irrespective of contribution or potential, and pipeline is deeply questionable